隐藏的火花:从冷到热在BRAF结肠直肠癌
1Oncology and Therapeutics Research, City of Hope Orange County, Irvine, CA 92618, USA.
Cancer cell
|October 10, 2025
概括
单剂PD-1阻塞免疫疗法对微卫星稳定的结直肠癌无效. 结合基因激活蛋白激酶 (MAPK) 途径向与免疫疗法,可以增强BRAF-V600E突变MSS结肠直肠癌的免疫反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 微卫星稳定性结直肠癌 (MSS) 在很大程度上对单剂PD-1阻断免疫疗法没有反应.
- BRAF-V600E突变在MSS结直肠癌中很常见,并且与预后不佳有关.
研究的目的:
- 研究结合基因激活蛋白激酶 (MAPK) 途径抑制与BRAF-V600E突变MSS结直肠癌免疫治疗的疗效.
- 为了确定这种组合疗法是否可以克服免疫治疗的耐药性,并增强抗瘤免疫反应.
主要方法:
- 使用了BRAF-V600E突变MSS结直肠癌的临床前模型.
- 联合治疗包括MAPK路径抑制剂和抗PD-1免疫疗法.
- 评估了瘤微环境,免疫细胞透和瘤生长.
主要成果:
- 针对MAPK途径与免疫疗法结合,重新编程了瘤微环境.
- 这种组合疗法导致免疫细胞透率增加并增强了抗瘤活性.
- BRAF-V600E突变MSS结肠直肠癌患者对免疫治疗的反应得到改善.
结论:
- 将MAPK通路抑制与免疫疗法结合起来,代表了治疗BRAF-V600E突变MSS结直肠癌的有希望的策略.
- 这种方法可以克服免疫疗法耐药性,并改善这种难以治疗的癌症患者的临床结果.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K


